Dr. Reddy''s Rings NYSE Closing Bell for 25 Years
Dr. Reddy's Laboratories marked its 25-year anniversary on the New York Stock Exchange (NYSE) by ringing the closing bell, with Chairman Satish Reddy emphasizing the company’s commitment to global governance and affordable healthcare innovation. The event highlighted the company’s status as the first Asian pharmaceutical firm outside Japan listed on the NYSE in April 2001, alongside its leadership team and key executives attending the ceremony at the NYSE headquarters." "article": "Dr. Reddy’s Laboratories celebrated its 25-year listing on the New York Stock Exchange (NYSE) by participating in the closing bell ceremony on May 30. Chairman Satish Reddy, accompanied by senior executives including CEO Erez Israeli, CEO-Global Generics MV Ramana, and CFO MV Narasimham, led the event at the NYSE headquarters in New York. The company became the first pharmaceutical firm from Asia, excluding Japan, to list on the NYSE in April 2001, marking a milestone in its global expansion. During the ceremony, Reddy emphasized that the 25-year anniversary was a testament to the company’s dedication to transparency, governance, and innovation. He credited the company’s founder, Dr. K Anji Reddy, for establishing a vision to provide affordable and innovative medicines worldwide, which continues to guide Dr. Reddy’s operations today. Executives such as Milan Kalawadia (CEO-North America), K Randhir Singh (Head-Company Secretary and CSR), and independent directors Arun M Kumar and Penny Wan also attended the event. Reddy dedicated the milestone to employees, partners, and shareholders, reaffirming the company’s mission to accelerate access to healthcare under the slogan ‘good health can’t wait.’ The NYSE closing bell ceremony symbolizes significant corporate milestones, and Dr. Reddy’s event underscored its long-standing presence as a trusted name in the U.S. pharmaceutical market. The company’s leadership highlighted its commitment to differentiated products and consistent operations as it looks to the future.
Dr. Reddy’s Laboratories celebrated its 25-year listing on the New York Stock Exchange (NYSE) by participating in the closing bell ceremony on May 30. Chairman Satish Reddy, accompanied by senior executives including CEO Erez Israeli, CEO-Global Generics MV Ramana, and CFO MV Narasimham, led the event at the NYSE headquarters in New York. The company became the first pharmaceutical firm from Asia, excluding Japan, to list on the NYSE in April 2001, marking a milestone in its global expansion. During the ceremony, Reddy emphasized that the 25-year anniversary was a testament to the company’s dedication to transparency, governance, and innovation. He credited the company’s founder, Dr. K Anji Reddy, for establishing a vision to provide affordable and innovative medicines worldwide, which continues to guide Dr. Reddy’s operations today. Executives such as Milan Kalawadia (CEO-North America), K Randhir Singh (Head-Company Secretary and CSR), and independent directors Arun M Kumar and Penny Wan also attended the event. Reddy dedicated the milestone to employees, partners, and shareholders, reaffirming the company’s mission to accelerate access to healthcare under the slogan ‘good health can’t wait.’ The NYSE closing bell ceremony symbolizes significant corporate milestones, and Dr. Reddy’s event underscored its long-standing presence as a trusted name in the U.S. pharmaceutical market. The company’s leadership highlighted its commitment to differentiated products and consistent operations as it looks to the future.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.